News
Stay up to date with Erudio Bio's latest research milestones, partnerships, and company announcements.
Erudio Bio Submits Comments to FDA to Modernize Drug Development
Erudio Bio submitted comments to the FDA's Request for Information on the Expedited Investigational New Drug Pilot Program, outlining a strategy to modernize the pre–first-in-human stage of drug development. The proposal calls for higher-fidelity, higher-throughput biophysical measurements integrated with AI and physics-based simulations anchored to experimental data, enabling developers to identify promising candidates earlier, eliminate likely failures before substantial resources are committed, and improve the quality and safety of IND submissions. Erudio Bio emphasized that adopting these advanced tools could accelerate clinical development, reduce costs and failure rates, and strengthen U.S. leadership in next-generation medicine.
https://www.regulations.gov/comment/FDA-2026-N-4699-0011Erudio Bio Receives Grant to Advance bioTCAD™ for global health
Erudio Bio today announced a grant from the Gates Foundation to support bioTCAD™, an AI platform that pairs advanced modeling with Erudio’s multiplex force-spectroscopy binding measurements. The project aims to make preclinical drug design more reliable and faster—ultimately lowering the cost of developing medicines for diseases that disproportionately affect people in low- and middle-income countries. “AI needs trustworthy experimental labels to predict what actually works,” said Kee-Hyun Paik, PhD, Erudio’s co-founder and CEO. “With the foundation’s funding support, we’ll scale bioTCAD to generate high-quality binding data and put it to work on high-burden diseases.”
Gates Foundation Erudio Bio GrantErudio Bio Announces Groundbreaking Collaboration with Shanghai General Hospital
Erudio Bio entered into a joint development agreement with Shanghai General Hospital's Laboratory Medicine Center to address the challenges of diagnosing uveitis through advanced multiplex biomarker testing. This partnership leverages Erudio's patented force spectroscopy technology and Shanghai General Hospital's expertise in clinical laboratory testing. Together, we aim to develop a unified diagnostic test kit for uveitis, marking a significant step in advancing precision diagnostics for complex eye diseases.
Erudio Bio Announces Partnership with Shanghai General Hospital for Ocular Biomarker Research
Erudio Bio, Inc., a leader in multiplex bio detection, is thrilled to announce a groundbreaking research partnership with Shanghai General Hospital, one of the world's leading healthcare institutions. This collaboration will focus on validating the use of Erudio's VSA prototype platform for multiplexed analysis of human ocular samples. The project aims to demonstrate how Erudio's technology can address the challenge of analyzing multiple biomarkers from the limited sample sizes typically available in ocular research.